Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Cytokine ; 96: 123-131, 2017 08.
Article in English | MEDLINE | ID: mdl-28399484

ABSTRACT

Administration of streptozotocin (STZ) is one of the most used experimental models of diabetes (STZ-DT). STZ induces beta-cell damage in pancreatic islets. It is known that hematopoietic stem progenitor cells (HSPCs) are mobilized from bone marrow to damaged tissues. In this work, we evaluated the effects of the hematopoietic mobilizers G-CSF (250µg/kg; for five consecutive days) and AMD3100 (5mg/kg; single s.c injection) in mice treated with STZ (175mg/kg). Mice injected with STZ showed a significant reduction in the number and area of islets and in the number of beta- and alpha-cells. Concurrently, they had hyperglycemia (blood glucose over 300mg/dl) associated with very low levels of insulin in plasma. The number and area of islets from STZ-DT mice treated with G-CSF and/or AMD3100 were similar to the controls. However, these mice had neither a reduction of hyperglycemia nor an improvement in the insulin levels. Analysis of islet cellularity showed a large reduction in beta-cells with a significant expansion of alpha-cells. These results indicate that G-CSF and AMD3100 induce partial protection of islet tissues and expansion of alpha-cells in mice treated with STZ but do not protect beta-cells from the damage induced by this compound.


Subject(s)
Glucagon-Secreting Cells/drug effects , Granulocyte Colony-Stimulating Factor/administration & dosage , Heterocyclic Compounds/administration & dosage , Islets of Langerhans/drug effects , Streptozocin/therapeutic use , Animals , Benzylamines , Blood Glucose , Cyclams , Diabetes Mellitus, Experimental , Glucagon-Secreting Cells/physiology , Hyperglycemia/etiology , Insulin/blood , Insulin-Secreting Cells/drug effects , Male , Mice , Streptozocin/administration & dosage
2.
Clin Sci (Lond) ; 128(11): 789-803, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25881670

ABSTRACT

The 70 kDa heat-shock protein (HSP70) family is important for a dynamic range of cellular processes that include protection against cell stress, modulation of cell signalling, gene expression, protein synthesis, protein folding and inflammation. Within this family, the inducible 72 kDa and the cognate 73 kDa forms are found at the highest level. HSP70 has dual functions depending on location. For example, intracellular HSP70 (iHSP70) is anti-inflammatory whereas extracellular HSP70 (eHSP70) has a pro-inflammatory function, resulting in local and systemic inflammation. We have recently identified a divergence in the levels of eHSP70 and iHSP70 in subjects with diabetes compared with healthy subjects and also reported that eHSP70 was correlated with insulin resistance and pancreatic ß-cell dysfunction/death. In the present review, we describe possible mechanisms by which HSP70 participates in cell function/dysfunction, including the activation of NADPH oxidase isoforms leading to oxidative stress, focusing on the possible role of HSPs and signalling in pancreatic islet α- and ß-cell physiological function in health and Type 2 diabetes mellitus.


Subject(s)
Diabetes Mellitus, Type 2/physiopathology , HSP70 Heat-Shock Proteins/metabolism , Islets of Langerhans/physiology , NADPH Oxidases/metabolism , Diabetes Mellitus, Type 2/metabolism , Extracellular Space/metabolism , Glucagon-Secreting Cells/metabolism , Glucagon-Secreting Cells/physiology , Humans , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/physiology , Intracellular Space/metabolism , Islets of Langerhans/metabolism , Signal Transduction/physiology
3.
PLoS One ; 9(4): e93531, 2014.
Article in English | MEDLINE | ID: mdl-24705399

ABSTRACT

Glucocorticoid (GC)-based therapies can cause insulin resistance (IR), glucose intolerance, hyperglycemia and, occasionally, overt diabetes. Understanding the mechanisms behind these metabolic disorders could improve the management of glucose homeostasis in patients undergoing GC treatment. For this purpose, adult rats were treated with a daily injection of dexamethasone (1 mg/kg b.w., i.p.) (DEX) or saline as a control for 5 consecutive days. The DEX rats developed IR, augmented glycemia, hyperinsulinemia and hyperglucagonemia. Treatment of the DEX rats with a glucagon receptor antagonist normalized their blood glucose level. The characteristic inhibitory effect of glucose on glucagon secretion was impaired in the islets of the DEX rats, while no direct effects were found on α-cells in islets that were incubated with DEX in vitro. A higher proportion of docked secretory granules was found in the DEX α-cells as well as a trend towards increased α-cell mass. Additionally, insulin secretion in the presence of glucagon was augmented in the islets of the DEX rats, which was most likely due to their higher glucagon receptor content. We also found that the enzyme 11ßHSD-1, which participates in GC metabolism, contributed to the insulin hypersecretion in the DEX rats under basal glucose conditions. Altogether, we showed that GC treatment induces hyperglucagonemia, which contributes to an imbalance in glucose homeostasis and compensatory ß-cell hypersecretion. This hyperglucagonemia may result from altered α-cell function and, likely, α-cell mass. Additionally, blockage of the glucagon receptor seems to be effective in preventing the elevation in blood glucose levels induced by GC administration.


Subject(s)
Blood Glucose/drug effects , Dexamethasone/adverse effects , Glucagon-Secreting Cells/physiology , Glucocorticoids/adverse effects , Homeostasis/drug effects , Hyperinsulinism/chemically induced , Insulin/metabolism , Animals , Blood Glucose/metabolism , Cells, Cultured , Dexamethasone/administration & dosage , Drug Administration Schedule , Glucagon-Secreting Cells/drug effects , Glucagon-Secreting Cells/pathology , Glucocorticoids/administration & dosage , Hyperinsulinism/blood , Injections, Intraperitoneal , Insulin Resistance , Insulin Secretion , Male , Rats , Rats, Wistar
4.
Math Biosci Eng ; 7(4): 793-807, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21077708

ABSTRACT

Pancreatic alpha cells synthesize and release glucagon. This hormone along with insulin, preserves blood glucose levels within a physiological range. During low glucose levels, alpha cells exhibit electrical activity related to glucagon secretion. In this paper, we introduce minimal state models for those ionic channels involved in this electrical activity in mice alpha cells. For estimation of model parameters, we use Monte Carlo algorithms to fit steady-state channel currents. Then, we simulate dynamic ionic currents following experimental protocols. Our aims are 1) To understand the individual ionic channel functioning and modulation that could affect glucagon secretion, and 2) To simulate ionic currents actually measured in voltage-clamp alpha-cell experiments in mice. Our estimations indicate that alpha cells are highly permeable to sodium and potassium which mainly manage action potentials. We have also found that our estimated N-type calcium channel population and density in alpha cells is in good agreement to those reported for L-type calcium channels in beta cells. This finding is strongly relevant since both, L-type and N-type calcium channels, play a main role in insulin and glucagon secretion, respectively.


Subject(s)
Glucagon-Secreting Cells/metabolism , Glucagon/metabolism , Ion Channels/physiology , Models, Biological , Action Potentials/physiology , Animals , Computer Simulation , Glucagon/physiology , Glucagon-Secreting Cells/physiology , Glucose/physiology , Insulin/metabolism , Insulin Secretion , Mice , Monte Carlo Method , Pancreas/metabolism
5.
PLoS One ; 1: e35, 2006 Dec 20.
Article in English | MEDLINE | ID: mdl-17183663

ABSTRACT

Function and structure of adult pancreatic islets are determined by early postnatal development, which in rats corresponds to the first month of life. We analyzed changes in blood glucose and hormones during this stage and their association with morphological and functional changes of alpha and beta cell populations during this period. At day 20 (d20), insulin and glucose plasma levels were two- and six-fold higher, respectively, as compared to d6. Interestingly, this period is characterized by physiological hyperglycemia and hyperinsulinemia, where peripheral insulin resistance and a high plasmatic concentration of glucagon are also observed. These functional changes were paralleled by reorganization of islet structure, cell mass and aggregate size of alpha and beta cells. Cultured beta cells from d20 secreted the same amount of insulin in 15.6 mM than in 5.6 mM glucose (basal conditions), and were characterized by a high basal insulin secretion. However, beta cells from d28 were already glucose sensitive. Understanding and establishing morphophysiological relationships in the developing endocrine pancreas may explain how events in early life are important in determining adult islet physiology and metabolism.


Subject(s)
Insulin/metabolism , Islets of Langerhans/growth & development , Islets of Langerhans/metabolism , Age Factors , Animals , Blood Glucose/metabolism , Cell Aggregation , Cell Count , Cells, Cultured , Diet , Glucagon/blood , Glucagon-Secreting Cells/metabolism , Glucagon-Secreting Cells/physiology , Insulin/blood , Insulin Resistance/physiology , Insulin Secretion , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/physiology , Islets of Langerhans/cytology , Islets of Langerhans/physiology , Male , Rats , Rats, Wistar , Weaning
SELECTION OF CITATIONS
SEARCH DETAIL